Log in to save to my catalogue

TFEB controls sensitivity to chemotherapy and immuno-killing in non-small cell lung cancer

TFEB controls sensitivity to chemotherapy and immuno-killing in non-small cell lung cancer

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_4a6851a8a8824044acb7cc89ddb408bf

TFEB controls sensitivity to chemotherapy and immuno-killing in non-small cell lung cancer

About this item

Full title

TFEB controls sensitivity to chemotherapy and immuno-killing in non-small cell lung cancer

Publisher

England: BioMed Central Ltd

Journal title

Journal of experimental & clinical cancer research, 2024-08, Vol.43 (1), p.219-23, Article 219

Language

English

Formats

Publication information

Publisher

England: BioMed Central Ltd

More information

Scope and Contents

Contents

In non-small cell lung cancer (NSCLC) the efficacy of chemo-immunotherapy is affected by the high expression of drug efflux transporters as ABCC1 and by the low expression of ABCA1, mediating the isopentenyl pyrophosphate (IPP)-dependent anti-tumor activation of Vγ9Vδ2 T-lymphocytes. In endothelial cells ABCA1 is a predicted target of the transcrip...

Alternative Titles

Full title

TFEB controls sensitivity to chemotherapy and immuno-killing in non-small cell lung cancer

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_4a6851a8a8824044acb7cc89ddb408bf

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_4a6851a8a8824044acb7cc89ddb408bf

Other Identifiers

ISSN

1756-9966,0392-9078

E-ISSN

1756-9966

DOI

10.1186/s13046-024-03142-4

How to access this item